[Federal Register Volume 79, Number 154 (Monday, August 11, 2014)]
[Notices]
[Pages 46847-46851]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-18870]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Announcement of Requirements and Registration for ``Follow that 
Cell'' Challenge

    Authority: 15 U.S.C. 3719.

SUMMARY: Through the ``Follow that Cell'' Challenge (the 
``Challenge''), the Single Cell Analysis Program (SCAP)--http://commonfund.nih.gov/Singlecell/index, a component of the National 
Institutes of Health Common Fund--http://commonfund.nih.gov/about, is 
searching for novel methods for analyzing dynamic states of individual 
cells that can serve as the basis for predicting alterations in cell 
behavior and function over time. The goal of the Challenge is to 
develop new tools and methods that allow time-dependent measurements at 
the single-cell level in a complex tissue environment in order to 
assess functional changes, provide information on the health status of 
a given cell, and help guide diagnosis and therapeutic treatments 
related to human disease states. Technological breakthroughs in this 
arena could allow researchers and physicians to identify rare cells in 
a mixed population, such as individual cells that can transform and 
become cancerous, cells that are latently infected with a pathogenic 
virus, or cells that develop resistance to drugs over time.
    The NIH Common Fund currently supports SCAP grants, the majority of 
which are associated with academic institutions. This Challenge, 
structured in two phases, will strengthen and complement the existing 
SCAP grant portfolio by reaching out to a more diverse population of 
innovators and solvers, including not only those who are from academic 
institutions but also those who are from research and development 
communities in the private sector and those who are outside biomedical 
disciplines. The NIH believes this Challenge will stimulate investment 
from both public and private sectors in single-cell analysis research 
and product development, which, in

[[Page 46848]]

turn, could lead to the development of more sensitive, robust, and 
cost-effective assay approaches, reagents, tools, and devices for basic 
research and clinical diagnosis.

DATES: 
Phase 1: Effective on August 15, 2014
Phase 1 Submission period ends: December 15, 2014, 11:59 p.m. ET
Phase 1 Judging Period: December 16, 2014, to February 16, 2015
Phase 1 Winners and other Finalists Announced: March 16, 2015
Phase 2 begins: March 17, 2015
Phase 2 Submission period ends: March 30, 2017, 11:59 p.m. ET
Phase 2 Judging Period: March 31, 2017, to June 30, 2017
Phase 2 Winners announced: July 31, 2017

    The NIH may shorten the submission period for Phase 2 and adjust 
dates for judging and winner(s) announcement if the Phase 1 winners' 
feasibility assessments suggest a shorter Phase 2 submission period is 
possible. The NIH will announce any changes to the timeline by amending 
this Federal Register notice no later than March 16, 2015. This 
Challenge will be administered by InnoCentive, Inc., on behalf of the 
NIH www.innocentive.com/followthatcell.

FOR FURTHER INFORMATION CONTACT: Yong Yao, Ph.D., NIH, 301-443-6102; or 
Erin Shannon, NIH, 301-443-3959.

SUPPLEMENTARY INFORMATION:

Subject of Challenge

    Many biological experiments are performed under the assumption that 
all cells of a particular ``type'' are identical. However, recent data 
suggest that individual cells within a single population may differ 
quite significantly, and these differences can drive the health and 
function of the entire cell population. Single-cell analysis comprises 
a broad field that covers advanced optical, electrochemical, mass 
spectrometry instrumentation, and sensor technology, as well as 
separation and sequencing techniques. Although the approaches currently 
in use can offer snapshots of single cells, the methods are often not 
amenable to longitudinal studies that monitor changes in individual 
cells in situ.
    In this Challenge, the NIH is seeking novel robust methods for 
analysis of individual cells that can detect and assess changes in cell 
behavior and function over time, either as a result of natural state 
changes or when perturbed (e.g., by a drug, biological stimulus, 
infectious agent, pathological lesion, or mechanical forces). It is 
hoped that such methods will yield creative and new, yet feasible, 
solutions for following a single cell over time in a complex 
multicellular environment to detect changing cell properties, 
preferably using multiple integrated measures.
    Solutions submitted to this Challenge should:
     Include measurements or assays that are nondestructive and 
capable of producing temporal data at the individual cell level 
starting with eukaryotic cells in a complex/mixed cell population;
     address at least one impactful, biological, or clinical 
question proposed by the Solver;
     demonstrate robust reproducibility;
     address gaps or deficiencies in current capabilities that 
may include but are not limited to:
    [cir] Tools that provide significant advances in sensitivity and 
selectivity in the spatiotemporal resolution of molecules/structures/
activities within single cells in situ (e.g., high resolution imaging 
of molecular interactions within single cells, molecular probes that 
are at least an order of magnitude smaller in size than existing 
versions of reporter molecules such as fluorescent proteins);
    [cir] Automated and scalable assays to detect meaningful functional 
changes in single cells in complex tissue environments that improve 
upon processing time and reduce overall cost; or
    [cir] New combinations of tools and approaches to maximize data 
generation over several parameters (e.g., proteins, lipids, 
metabolites, signal secretion/reception/transduction, migratory 
changes);
     advance what is currently considered the state-of-the-art.

Solutions describing existing, well-established and/or currently 
supported approaches, especially commonly used strategies are not of 
interest unless a compelling case is made that significant, 
quantifiable advances are proposed and/or the methods and measures are 
used in unique combinations that have not been previously tested 
together for the analysis of individual cells in complex environments.
    We welcome solutions from individuals, teams, and entities from all 
U.S. sources, including the public sector, private sector, and 
nonprofit groups.

Eligibility Rules for the Challenge

1. To Participate

    This Challenge is open to any ``Solver'' where ``Solver'' is 
defined as an individual, a group of individuals (i.e., a team), or an 
entity. Whether singly or as part of a group or entity, each individual 
participating in the Challenge must be 18 years of age or older.
    Eligibility to participate in Phase 2 of the Challenge is 
conditioned upon participation in Phase 1 of the Challenge and being 
selected as a ``Phase 1 Finalist.'' Phase 1 Finalists are any and all 
Phase 1 prize winners and any individual, team, and/or entity whose 
solution received a meritorious rating based on the judging criteria.

2. To Win

    To be eligible to win a prize under this Challenge, the Solver--
    1. Shall have registered to participate in the Challenge under the 
process identified at the InnoCentive Web site www.innocentive.com/followthatcell.
    2. Shall have complied with all the requirements under this section 
on Eligibility.
    3. In the case of a private entity, shall be incorporated in and 
maintain a primary place of business in the United States; and in the 
case of an individual, whether participating singly or in a group, 
shall be a citizen or permanent resident of the United States. Note: 
Non-U.S. citizens and nonpermanent residents can participate as a 
member of a team that otherwise satisfies the eligibility criteria but 
will not be eligible to win a monetary prize (in whole or in part); 
however, their participation as part of a winning team, if applicable, 
may be recognized when results are announced.
    4. In the case of an individual, he/she may not be an employee of 
the NIH; an individual involved in formulation of the Challenge and/or 
serving on the technical evaluation panel; any other individual 
involved with the design, production, execution, distribution, or 
evaluation of this Challenge; or members of the individual's immediate 
family (specifically, a parent, step-parent, spouse, domestic partner, 
child, sibling, or step-sibling).
    5. An individual, team, or entity that is currently on the Excluded 
Parties List (https://www.epls.gov/) will not be selected as a Finalist 
or prize winner.
    6. In the case of an entity, may not be a federal entity; and in 
the case of an individual, may not be a federal employee acting within 
the scope of his or her employment.
    7. Federal employees otherwise permitted to participate in the 
Challenge shall not work on their submission during assigned duty 
hours. Note: Federal ethical conduct rules may restrict or prohibit 
federal employees from engaging in certain outside

[[Page 46849]]

activities, so any federal employee not excluded under the prior 
paragraph seeking to participate in this Challenge outside the scope of 
employment should consult his/her agency's ethics official prior to 
developing a submission.
    8. Federal grantees may not use federal funds to develop Challenge 
submissions.
    9. Federal contractors may not use federal funds from a contract to 
develop Challenge submissions or to fund efforts in support of a 
Challenge submission.
    10. An individual shall not be deemed ineligible to win because the 
individual used federal facilities or consulted with federal employees 
during the Challenge provided that such facilities and/or employees, as 
applicable, are made available on an equitable basis to all individuals 
and teams participating in the Challenge.
    All questions regarding the Challenge should be directed to Dr. Yao 
or Ms. Shannon, identified above, and answers will be posted and 
updated as necessary at www.innocentive.com/followthatcell under 
Frequently Asked Questions. Questions from Solvers that may reveal 
proprietary information related to solutions under development may be 
addressed in the InnoCentive project room, an online secure and 
confidential communication forum.

Submission Requirements

    The Challenge has two phases.
    Phase 1 (Theoretical)--Phase 1 of the Challenge requires a written 
proposed solution which describes a novel method for analyzing dynamic 
states of individual cells that can serve as the basis for predicting 
alterations in cell behavior and function over time.
    The Phase 1 Submission shall include:
    1. A comprehensive description of the proposed solution in 10 pages 
or less, 8.5 x 11 inch page, 10-point font or greater and one inch 
margins including:
    a. A one-paragraph executive summary that clearly states the 
biological or clinical question to be solved;
    b. Background information supporting the significance of the 
biological or clinical question(s) and the proposed approach, pitfalls, 
and validation scheme that addresses efforts to support 
reproducibility; if possible, citing selected peer-reviewed articles 
that strengthen the proposed solution. The full citations for articles 
should be included in the references section;
    c. Descriptions of methods and technologies key to implementation; 
and
    d. A ``State-of-the-Art'' Statement that describes approaches 
currently in use (if any) and clearly explains how the methods and 
measures proposed advance existing capabilities.
    2. A biographical sketch, in no more than four pages, of your 
experience and relevant expertise required to validate the proposed 
solution, including publications, if applicable. Team submissions 
should include a biosketch for each team member.
    3. A feasibility assessment and a statement describing your ability 
to execute the proposed solution in Phase 2 (Reduction to Practice), 
including the estimated timeframe, supporting precedents, and any 
special resource(s) you may have or will need. If relevant, the 
assessment of feasibility should also address Protections for Humans 
Subjects, compliance with policies related to the use of vertebrate 
animals, biosafety issues, and use of methods/technologies covered by 
patents or other intellectual property protection, as applicable.
    4. List of essential materials and reagents including their 
suppliers, if applicable.
    5. Appendices describing existing, unpublished experimental data 
that support your proposed solution may be included. Please note that 
while a page limit is not placed on appendices, please be concise in 
your presentation and include only relevant data in support of your 
solution.
    6. References.
    All Phase 1 Solvers will agree to allow the executive summaries of 
their solutions to be posted on the NIH Common Fund Web site.
    Phase 2 (Reduction to Practice)--All Phase 1 Finalists will be 
eligible to participate as Phase 2 Solvers in the second phase of the 
Challenge to produce proof-of-concept data. Phase 2 Solvers will 
execute their proposed solution(s) to Phase 1 of the Challenge and 
submit (in the Phase 2 submission) single cell data addressing 
significant biological or clinical question(s) by measuring changes in 
a single cell over time. Phase 2 Solvers are encouraged to incorporate 
the expert review feedback from Phase 1 and form teams/partnerships to 
improve the likelihood of successful solution implementation. Detailed 
submission requirements for Phase 2 of the Challenge will be available 
to Phase 2 Solvers no later than 30 days after the Phase 1 Finalists 
are announced.
    The Phase 2 submission shall include:
    1. Project Description: Detailed description of materials, methods, 
personnel, resources, and schedule.
    2. Execution: Successful generation of time course measurements 
from a single cell based on the Phase 1 solution, which may also 
include innovations, essential alterations in the proposed plan, and/or 
trouble-shooting technical or analytical challenges. Any changes from 
the original design (Phase 1 solution) should be documented and 
explained.
    3. Data: Quality and significance of the time course data produced; 
efforts to assess reproducibility.

Registration and Submission Process for Solvers

    To register and submit for this Challenge, Solvers may access the 
registration and submission platform from any of the following:
     Access the www.challenge.gov Web site and search for 
``Follow that Cell.''
     Access the NIH Single Cell Analysis Web site https://commonfund.nih.gov/Singlecell/index; a registration link for the 
Challenge can be found on the landing page under Challenge Description.
     Access the Innocentive Challenge Web site at 
www.innocentive.com/followthatcell.

Amount of the Prize.

    Phase 1: $100,000.
    Phase 2: $400,000.
    As determined by the judges, up to six prizes may be awarded for 
Phase 1 solutions from a total prize award pool of $100,000, and up to 
2 prizes may be awarded for Phase 2 solutions from a total pool of 
$400,000.
    In addition, any and all Phase 1 Finalists will be acknowledged by 
the NIH Common Fund Single Cell Analysis Program and invited to attend 
The 3rd Annual Single Cell Analysis Investigators Meeting near 
Bethesda, Maryland, U.S.A., on April 20-21, 2015, during which they may 
be invited to present their theoretical solution. Any funds for travel 
reimbursements for Phase 1 winners will be counted within the total 
prize amounts.
    Note that in the event a winning team includes individual members 
who are neither citizens nor permanent residents of the United States, 
these individuals are welcome to attend the meeting and their names 
will be listed among the team members, but they cannot be reimbursed 
for their travel and related expenses.
    The NIH reserves the right to cancel, suspend, and/or modify this 
Challenge at any time through amendment to this Federal Register 
notice. In addition, the NIH reserves the right to not award any prizes 
if no solutions are deemed worthy. The award approving official for 
Phase 1 and Phase 2 of this Challenge is the NIH Principal Deputy 
Director.

[[Page 46850]]

Basis Upon Which Winners Will Be Evaluated

    Solutions for both phases of the Challenge will be evaluated by a 
Technical Evaluation Panel using the criteria and rating scales 
describe below. NIH scientific staff from the various Institutes and 
Centers (ICs), including the Office of Strategic Coordination, will 
review highly rated solutions for scientific alignment to the single-
cell analysis program, relevance to the NIH mission, and potential 
overlap with existing projects. The judges, comprising three senior NIH 
leaders, will use the technical and programmatic evaluations to 
determine the Phase 1 prize winners, those Solvers in Phase 1 who are 
deemed meritorious, and the Phase 2 prize winner(s). Prizes will be 
approved by the NIH Principal Deputy Director.
    Phase 1 (Theoretical)--The technical evaluation panel will use the 
following criteria and rating scales for evaluating proposed solutions 
with high scores reflecting the mostly highly rated solutions: (Maximum 
100 points; plus bonus points)
    1. Time Course Measurements--Must permit time course measurements 
on the same cell over a biologically significant period of time rather 
than a single, snapshot assessment; provide rationale for the 
functional measure(s) and chosen duration. (0-25 points)
    2. Predictability--Approach must provide technical requirements 
(sensitivity, selectivity, spatiotemporal resolution, signal-to-noise 
ratio, etc.) that will adequately support robust prediction of 
phenotypic changes in cell state that occur naturally or in response to 
controlled perturbation(s). (0-20 points)
    3. Cellular Environment--Must pertain to single cells in a complex 
multicellular environment with preference for cell types that are 
phylogenetically closer to human (a-d below ordered from highest to 
lowest in interest). (0-20 points)

a. Multicellular living organism (15-20 points)
b. Intact tissue (10-15 points)
c. Organoid culture (5-10 points)
d. Cell culture (0-5 points)

    4. Significance--Must address a meaningful biological or clinical 
question with high potential impact if successful; must advance current 
capabilities and address issues related to reproducibility. (0-20 
points)
    5. Adaptability--Must describe broad utility and scalability. The 
approach should lend itself to more than one particular cell type. (0-
15 points)
    Bonus Points. (Maximum 50 bonus points)
     Feasibility--Should provide sufficient details to support 
the feasibility that the proposed solution will be reduced to practice 
in less than two years, including published or unpublished data, 
scientific basis, technological capability, and resources. (Bonus up to 
30 points)
     Throughput--Methods that describe multiplexed analysis to 
increase throughput and coverage will be rated more favorably. (Bonus 
up to 10 points)
     Data Content--Methods that promote the collection and 
integration of multiple types of data (e.g., biochemical, physiologic, 
morphological, or `omics-level analyses) on individual cells will be 
rated more favorably. (Bonus up to 10 points)
    Phase 2 (Reduction to Practice)--Phase 2 submissions must provide a 
clear description of how experiments were conducted (including use of 
appropriate controls, instrument calibration, etc.) and how the data 
were collected. Phase 2 submissions must include all requisite 
scientific and technical details including materials, methods, 
protocols, and devices to demonstrate successful execution of the 
proposed solution. It should also document trouble-shooting: What 
technical or analytical challenges were encountered and how were these 
resolved? Has reproducibility of the approach been demonstrated? What 
improvements and/or innovations were implemented above and beyond what 
was proposed in Phase 1?
    The technical evaluation panel will use the following criteria and 
rating scales for evaluating proposed Phase 2 solutions, with high 
scores reflecting the mostly highly rated solutions. (Maximum 100 
points, plus bonus points)
    1. Time Course Measurements--Must provide time course measurement 
data on the same cell over a biologically significant period of time 
with adequate time intervals. (0-25 points)
    2. Predictability--Approach must provide technical specifications 
(sensitivity, selectivity, spatiotemporal resolution, signal-to-noise 
ratio, etc.) that will adequately support robust prediction of 
phenotypic changes in cell state that occur naturally or in response to 
controlled perturbation(s). The data should also support robustness, 
stability, and reproducibility of measurements. (0-20 points)
    3. Cellular Environment--Must provide measurement data pertaining 
to single cells in a complex multicellular environment with preference 
for cell types that are phylogenetically closer to human; (a-d below 
ordered from greatest to least in interest). (0-20 points)

    a. Multicellular living organism (15-20 points)

    b. Intact tissue (10-15 points)

    c. Organoid culture (5-10 points)

    d. Cell culture (0-5 points)

    4. Significance--Must address a meaningful biological or clinical 
question with high potential impact if successful; must make technical 
advances and/or improvements to existing methods and approaches. Should 
provide evidence of reproducibility. (0-20 points)
    5. Adaptability--Must describe broad utility and scalability. The 
approach should lend itself to more than one particular cell type. (0-
15 points)
    Bonus Points (maximum 20 bonus points)
     Throughput Methods that promote multiplexed analysis to 
increase throughput and coverage will be rated more favorably. (Bonus 
up to 10 points)
     Data Content Methods that collect and integrate multiple 
types of data (e.g., biochemical, physiologic, morphological, or 
`omics-level analyses) on individual cells will be rated more 
favorably. (Bonus up to 10 points)
    As part of the evaluation process, the panel may request a 
demonstration of the technology.

Additional Information

Statutory Authority of the Funding Source

    This Challenge is consistent with and advances the mission of the 
NIH Division of Program Coordination, Planning, and Strategic 
Initiatives to identify research that represents important areas of 
emerging scientific opportunities, rising public health challenges, or 
knowledge gaps that deserve special emphasis, including coordination of 
the NIH Common Fund. The NIH Common Fund was enacted into law by 
Congress through the 2006 National Institutes of Health Reform Act to 
support cross-cutting, trans-NIH programs that require participation by 
at least two NIH ICs or would otherwise benefit from strategic planning 
and coordination. The requirements for the NIH Common Fund encourage 
collaboration across the ICs while providing the NIH with flexibility 
to determine priorities for Common Fund support. To date, the Common 
Fund has been used to support a series of short-term, exceptionally 
high-impact, trans-

[[Page 46851]]

NIH programs. http://commonfund.nih.gov/about.
    Intellectual Property: By submitting the Submission, each Solver 
warrants that he or she is the sole author and owner of any 
copyrightable works that the Submission comprises, that the works are 
wholly original with the Solver (or is an improved version of an 
existing work that the Solver has sufficient rights to use and 
improve), and that the Submission does not infringe any copyright or 
any other rights of any third party of which Solver is aware.
    To receive an award, Solvers will not be required to transfer their 
exclusive intellectual property rights to the NIH. Instead, Solvers 
will grant to the federal government a nonexclusive license to practice 
their solutions and use the materials that describe them. To 
participate in the Challenge, each Solver must warrant that there are 
no legal obstacles to providing a nonexclusive license of Solver's 
rights to the federal government. This license will grant to the United 
States government a nonexclusive, nontransferable, irrevocable, paid-up 
license to practice or have practiced for or on behalf of the United 
States throughout the world any invention made by the Solvers that 
covers the Submission. In addition, the license will grant to the 
federal government and others acting on its behalf, a paid-up, 
nonexclusive, irrevocable, worldwide license in any copyrightable works 
that the Submission comprises, including the right to reproduce, 
prepare derivative works, distribute copies to the public, and perform 
publicly and display publicly said copyrightable works.
    Liability and Indemnification: By participating in this Challenge, 
each Solver agrees to assume any and all risks and waive claims against 
the federal government and its related entities, except in the case of 
willful misconduct, for any injury, death, damage, or loss of property, 
revenue, or profits, whether direct, indirect, or consequential, 
arising from participation in this Challenge, whether the injury, 
death, damage, or loss arises through negligence or otherwise. By 
participating in this Challenge, each Solver agrees to indemnify the 
federal government against third party claims for damages arising from 
or related to Challenge activities.
    Insurance: Based on the subject matter of the Challenge, the type 
of work that it will possibly require, as well as an analysis of the 
likelihood of any claims for death, bodily injury, or property damage, 
or loss potentially resulting from competition participation, Solvers 
are not required to obtain liability insurance or demonstrate financial 
responsibility in order to participate in this Challenge.
    Privacy, Data Security, Ethics, and Compliance: Solvers are 
required to identify and address privacy and security issues in their 
proposed projects and describe specific solutions for meeting them. In 
addition to complying with appropriate policies, procedures, and 
protections for data that ensures all privacy requirements and 
institutional policies are met, use of data should not allow the 
identification of the individual from whom the data was collected. 
Solvers are responsible for compliance with all applicable federal, 
state, local, and institutional laws, regulations, and policies. These 
may include, but are not limited to, Health Information Portability and 
Accountability Act (HIPAA) protections, Department of Health and Human 
Services (HHS) Protection of Human Subjects regulations, and Food and 
Drug Administration (FDA) regulations. If approvals (e.g., from an 
Institutional Review Board) will be required to initiate project 
activities in Phase 2, it is recommended that Solvers apply for 
approval at or before the Phase 1 submission deadline. The following 
links are intended as a starting point for addressing regulatory 
requirements but should not be interpreted as a complete list of 
resources on these issues:

HIPAA

Main link: http://www.hhs.gov/ocr/privacy/index.html.
Summary of the HIPAA Privacy Rule: http://www.hhs.gov/ocr/privacy/hipaa/understanding/summary/index.html.
Summary of the HIPAA Security Rule: http://www.hhs.gov/ocr/privacy/hipaa/understanding/srsummary.html.

Human Subjects--HHS

Office for Human Research Protections: http://www.hhs.gov/ohrp/index.html.
Protection of Human Subjects Regulations: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html.
Policy & Guidance: http://www.hhs.gov/ohrp/policy/index.html.
Institutional Review Boards & Assurances: http://www.hhs.gov/ohrp/assurances/index.html.

Human Subjects--FDA

Clinical Trials: http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm.
Office of Good Clinical Practice: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OfficeofScienceandHealthCoordination/ucm2018191.

Consumer Protection--Federal Trade Commission

Bureau of Consumer Protection: http://business.ftc.gov/privacy-and-security.

Challenge Judges

Director, Division of Program Coordination, Planning, and Strategic 
Initiatives, NIH.
Director, National Institute of Mental Health.
Director, National Institute of Biomedical Imaging and Bioengineering 
(NIBIB).

Acknowledgements

    The National Institutes of Health Single Cell Analysis Program team 
would like to thank the following Subject Matter Experts for providing 
guidance to our contractor, InnoCentive, as NIH staff developed this 
Challenge.

Ronald N. Germain, M.D., Ph.D., NIH, National Institute of Allergy and 
Infectious Diseases, Laboratory of Systems Biology
Leroy Hood, M.D., Ph.D., President, Institute for Systems Biology
Tom Misteli, Ph.D., NIH, National Cancer Institute, Laboratory of 
Receptor Biology and Gene Expression
 Pamela Gehron Robey, Ph.D., NIH, National Institute of Dental and 
Craniofacial Research, Craniofacial and Skeletal Diseases Branch
 Hari Shroff, Ph.D., NIH, NIBIB, High Resolution Optical Imaging 
Laboratory

    Dated: August 4, 2014.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.
[FR Doc. 2014-18870 Filed 8-8-14; 8:45 am]
BILLING CODE 4140-01-P